Oliceridine vs Sufentanil for Cough During Anesthesia Induction

Recruiting now · Phase 4

Conditions studied: Cough, Anesthesia

In brief

Sufentanil is the most widely used opioid analgesic for general anaesthesia induction; however, rapid intravenous bolus injection frequently triggers sufentanil-induced cough (SIC). In high-risk patients, SIC can cause abrupt elevation of intracranial and intraocular pressure and severe haemodynamic instability, posing a meaningful safety risk during the induction period. Oliceridine, the first G protein-biased μ-opioid receptor agonist approved by the Food and Drug Administration in 2020, provides analgesia through μ-receptor activation while substantially reducing β-arrestin-2 recruitment. This biased signalling profile is hypothesised to raise the excitation threshold of airway C-fibres and thereby reduce the incidence of cough. This prospective, single-centre, randomised, double-blind, parallel-group controlled trial directly compares oliceridine with sufentanil for general anaesthesia induction with respect to cough incidence, cough severity, haemodynamic responses, and perioperative safety, with the aim of providing evidence-based guidance for opioid selection during induction.

Key facts

Study ID

NCT07660380

Run by

Shiyou Wei

People needed

62

Starts

2026-06-27

Expected to finish

2026-07-28

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18 to 99 years.
• American Society of Anesthesiologists (ASA) physical status classification I, II, or III.
• Body mass index (BMI) between 18.5 and 28.0 kg/m².
• Scheduled for elective surgery under general anaesthesia.
• Able to understand the study procedures and provide written informed consent.

You may not qualify if…

• Preoperative upper respiratory tract infection symptoms (e.g., cough, expectoration, or fever) or a history of bronchial asthma or other conditions associated with increased airway reactivity.
• Severe cardiovascular disease (e.g., uncontrolled hypertension, recent myocardial infarction, or serious arrhythmia) or hepatic or renal dysfunction.
• Long-term opioid use, defined as continuous opioid use for more than 2 weeks within the 3 months prior to surgery.
• Known hypersensitivity to any study drug or anaesthetic agent used in this protocol.
• Anticipated difficult airway requiring awake intubation.
• Pregnancy or breastfeeding.

Where it is running

• Tianmen First People's Hospital — Tianmen, Hubei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.